SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors show strong conviction in its proprietary Alpha DaRT oncology platform, bolstered by recent Japanese marketing approval and upcoming trial milestones. The community is actively discussing the stock's robust cash position, the absence of dilution risk, and the belief that the company is significantly undervalued as it transitions into a commercial-stage player.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending as investors react to a 31.5% stake acquisition of Distributed Technologies Research, a move that has fueled intense community debate over potential dilution versus strategic expansion into AI-driven finance. Traders are also closely watching the ticker's high beta to Bitcoin, with many speculating on upcoming announcements at the company's investor day as they weigh the stock's long-term potential against past patterns of volatility.

Praetorian Acquisition Corp. - Ordinary Shares - Class A

Investors are closely monitoring Praetorian Acquisition Corp. following its recent public debut as the market evaluates the potential for future merger and acquisition activity from the newly formed blank check company.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending as investors weigh its aggressive pivot toward private credit and AI-driven infrastructure against lingering concerns regarding industry-wide redemption pressures and valuation risks in the real estate sector. The community is sharply divided, with some betting on a long-term turnaround fueled by record dry powder and strategic deployment, while others are closely monitoring potential liquidity constraints that could signal broader credit cycle risks.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is currently seeing significant momentum as investors digest its latest quarterly results, which showcased accelerating revenue growth and improved margins that suggest its AI-driven model is gaining traction. The stock remains a focal point for the retail community, who are actively debating its valuation versus its disruptive potential, while some traders continue to monitor for short-squeeze opportunities driven by high short interest and institutional interest.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending as investors closely monitor for a potential tenant announcement following the recent appointment of a new CFO with an extensive background in data center financing. Community sentiment remains polarized, with many long-term shareholders bullish on the company's behind-the-meter energy strategy while others express frustration over the timing of promised project developments.

Rydex Investments - Invesco CurrencyShares Canadian Dollar Trust

Invesco CurrencyShares Canadian Dollar Trust

The Canadian dollar is experiencing heightened volatility as investors weigh persistent trade-policy uncertainties and fluctuating crude oil prices against the Bank of Canada's cautious interest rate approach. The community is actively debating the potential for further easing, keeping a close watch on how shifting trade relations and economic data impact the currency's near-term trajectory.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is experiencing significant market interest following a strong quarterly earnings report that featured a double beat on top and bottom-line expectations and raised forward-looking guidance. The community is actively discussing the stock's impressive post-earnings price surge, debating the sustainability of its robotic surgery market dominance against potential margin pressures from tariffs and broader sector volatility.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is under intense pressure as it faces a convergence of leadership uncertainty, retail demand concerns, and a contentious public dispute between the founder and the current board. Community discourse is heavily focused on the stock's multi-year lows, with traders debating whether these valuation levels represent a generational buying opportunity or a deeper value trap as the company struggles to reclaim its former market dominance.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense market attention and high trading volume as investors position themselves ahead of the major OFC and GTC conferences, which the community views as critical catalysts for showcasing their optical interposer and external light source technologies. Sentiment is driven by speculation regarding potential new commercial partnerships or orders, with traders actively debating the stock's potential for a breakout amid heavy institutional accumulation and volatility around options expiration.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC

Almitas Capital LLC trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 71.4% during the third quarter, according to the company in its most recent 13F filing with...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been assigned an average recommendation of "Hold" from the six research firms that are currently covering the stock, MarketBeat...

Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon

Zentalis Pharmaceuticals (NASDAQ:ZNTL) executives outlined a strategy centered on advancing its WEE1 inhibitor azenosertib toward potential approval in platinum-resistant ovarian cancer (PROC...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the recipient of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling...

Vincent Vultaggio Sells 29,951 Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) insider Vincent Vultaggio sold 29,951 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, February 6th. The stock...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Insider Vincent Vultaggio Sells 6,894 Shares

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) insider Vincent Vultaggio sold 6,894 shares of the company's stock in a transaction dated Tuesday, February 10th. The shares were sold...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the target of a large decline in short interest in December. As of December 31st, there was short interest totaling 4,111,105...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Hold" by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have been given an average rating of "Hold" by the seven brokerages that are presently covering the firm, Marketbeat Ratings...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus rating of "Hold" from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports...

Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold

Wall Street Zen raised shares of Zentalis Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday...

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

ZNTL
Zentalis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ZNTL News

ZNTLZentalis Pharmaceuticals Inc